An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers
- 7 October 2013
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 22 (2) , 116-122
Abstract
Human epidermal growth factor receptor 2 (HER2) expression has been shown to be increased in several types of human tumours. In this study, for the imaging of HER2-related tumours, a modified RNA aptamer with HER2-specific targeting was labelled with 99mTc, by using hydrazino nicotinamide (HYNIC) as the chelator in the presence of tricine or ethylenediamine-N,N′-diacetic acid (EDDA) as the co-ligand. Stability testing of the radiolabelled aptamers in the serum was performed through SDS-PAGE. The aptamer–radionuclide conjugate was evaluated for its cellular HER2-specific binding in ovarian cancer cells (SKOV-3), and its biodistribution properties were assessed in normal and SKOV-3 tumour-bearing mice. In the presence of either tricine or EDDA, the HYNIC-RNA aptamers were labelled with 99mTc at a high yield and radiochemical purity. Cellular experiments confirmed the specific binding of the RNA aptamer to the HER2 receptor. In the animal biodistribution study, uptake of the EDDA-co-liganded 99mTc-HYNIC-RNA aptamer by the liver and spleen was remarkably lower than that of the aptamer with tricine. Tumours also showed a higher accumulation of radioactivity with the EDDA-co-liganded aptamer complex. This study demonstrated EDDA to be better than tricine for use as a co-ligand with the RNA aptamer, which can be a potential tool for the molecular imaging of HER2-overexpressing cancers.Keywords
This publication has 26 references indexed in Scilit:
- Aptamers and Their Biological ApplicationsSensors, 2012
- Molecular Imaging of MDM2 Messenger RNA with 99mTc-Labeled Antisense Oligonucleotides in Experimental Human Breast Cancer XenograftsJournal of Nuclear Medicine, 2010
- A census of amplified and overexpressed human cancer genesNature Reviews Cancer, 2010
- 99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In VivoJournal of Nuclear Medicine, 2009
- Imaging of HER-2 Overexpression in Tumors for Guiding TherapyCurrent Pharmaceutical Design, 2008
- Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequenceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Adaptive Recognition by Nucleic Acid AptamersScience, 2000
- 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistributionNuclear Medicine and Biology, 1999